(Q36553976)

English

Abacavir/lamivudine versus tenofovir/emtricitabine in virologically suppressed patients switching from ritonavir-boosted protease inhibitors to raltegravir

scientific article published on 24 September 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Abacavir/lamivudine versus tenofovir/emtricitabine in virologically suppressed patients switching from ritonavir-boosted protease inhibitors to raltegravir (English)

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

tenofovir/emtricitabine

1 reference

based on heuristic

inferred from title

abacavir/lamivudine

1 reference

based on heuristic

inferred from title

author name string

Esteban Martínez

1

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Polyana M d'Albuquerque

2

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Ignacio Pérez

3

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Judit Pich

4

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

José M Gatell

5

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

publication date

24 September 2012

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

AIDS Research and Human Retroviruses

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

29

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

2

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

235-241

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3552169

30 September 2017

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3552169

30 September 2017

Durability and outcome of initial antiretroviral treatments received during 2000--2005 by patients in the Swiss HIV Cohort Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3552169

30 September 2017

Principles and practice of HIV-protease inhibitor pharmacoenhancement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3552169

30 September 2017

Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3552169

30 September 2017

A pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naïve HIV-1-infected patients: 48-week results of the SHIELD trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3552169

28 June 2018

Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3552169

21 September 2018

96-week results of a pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naïve HIV-1-infected patients: the SHIELD trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3552169

21 September 2018

Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3552169

21 September 2018

Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3552169

21 September 2018

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3552169

21 September 2018

Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3552169

21 September 2018

Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3552169

21 September 2018

Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3552169

21 September 2018

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3552169

21 September 2018

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3552169

21 September 2018

A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3552169

21 September 2018

The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3552169

21 September 2018

Interval estimation for the difference between independent proportions: comparison of eleven methods

1 reference

https://pubmed.ncbi.nlm.nih.gov/22916715

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

1 reference

https://pubmed.ncbi.nlm.nih.gov/22916715

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Documento de consenso de GESIDA/ Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero 2011)

1 reference

https://pubmed.ncbi.nlm.nih.gov/22916715

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1089/AID.2012.0150

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36553976&oldid=1637574292"